Floatz logo

Capecitabine

First-Line

Cancer Institute and Hospital, Chinese Academy of Medical SciencesSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the First-Line cohort.

Asset / SponsorPhaseRating
Carboplatin
Danish Oncological Lung Cancer Group
Phase 3B
ETOPOSIDE
Danish Oncological Lung Cancer Group
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Danish Oncological Lung Cancer Group
Phase 3B
Hycamtin
Danish Oncological Lung Cancer Group
Phase 3B
Irinotecan
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC

View all 9 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →